BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax (VCT/ABT-199) is the first highly selective oral BCL-2 antagonist licensed by the FDA for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion (18) and for patients age 75 and older with newly diagnosed AML or who have complications that made intensive induction chemotherapy ineligible.